Lehman Brothers UK Capital Funding V LP
3.2.2026 16:00:00 CET | Globenewswire | Press release
Lehman Brothers UK Capital Funding V LP: Notice to Holders of Preferred Securities
Lehman Brothers UK Capital Funding V LP: Notice to Holders of Preferred Securities
LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) --
NOTICE TO THE HOLDERS OF:
USD 500,000,000 FIXED RATE ENHANCED CAPITAL ADVANTAGED PREFERRED SECURITIES ("LP V ECAPS")
ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING V LP ("LP V")
ISIN: XS0301813522
LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP V ECAPS
THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER.
Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP V and the LP V ECAPS. In order to view the formal notice, it is recommended that you copy and paste the link into your browser.
http://www.rns-pdf.londonstockexchange.com/rns/5115R_1-2026-2-3.pdf
If you have any difficulties in opening the link, please contact Samantha Hawkins at RSM UK Restructuring Advisory LLP by e-mail: Samantha.Hawkins@rsmuk.com.
Dated: 3 February 2026
This notice is given by
Matthew Haw
RSM UK Restructuring Advisory LLP
as Joint Liquidator of LB GP No.1 Ltd
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Neomorph, Inc.3.2.2026 19:08:00 CET | Press release
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Novo Nordisk A/S3.2.2026 17:38:27 CET | Press release
Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
Novo Nordisk A/S3.2.2026 17:37:17 CET | Press release
Novo Nordisk releases 2026 sales and operating profit outlook
Danske Bank A/S3.2.2026 17:21:36 CET | Press release
Danske Bank A/S, transactions by persons discharging managerial responsibilities
Danske Bank A/S3.2.2026 17:21:36 CET | Pressemeddelelse
Danske Bank A/S, ledende medarbejderes transaktioner
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom